Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03187288 | Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS | completed | Phase 1 | 13 | University Health Network, TorontoOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04429191 | JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation | completed | Phase 1 | 32 | Jasper Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07295951 | A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia | completed | Phase 1 | 6 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05918692 | A Phase 1 Study of BMF-500 in Adults With Acute Leukemia | completed | Phase 1 | 35 | Biomea Fusion Inc.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03588078 | Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | completed | Phase 1 / Phase 2 | 53 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04547062 | Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)(Tocilam) | completed | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05282459 | Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation | completed | Phase 1 / Phase 2 | 17 | Tian Yi ZhangOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04330820 | Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)(RELAX) | completed | Phase 1 / Phase 2 | 55 | Technische Universität DresdenOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02494167 | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) | completed | Phase 1 | 30 | Baylor College of MedicineOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT00720785 | Natural Killer Cells and Bortezomib to Treat Cancer | completed | Phase 1 | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT02732184 | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS | completed | Phase 1 | 21 | Immedica Pharma ABINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT06006403 | Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | completed | Phase 1 / Phase 2 | 5 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02971397 | Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 40 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03374332 | Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 11 | Brown UniversityOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02719574 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | completed | Phase 1 / Phase 2 | 336 | Forma Therapeutics, Inc.INDUSTRY | 9 | Jun 29, 2026 | clinicaltrials |
| NCT00081874 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04848974 | Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02158858 | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies | completed | Phase 1 / Phase 2 | 336 | Constellation PharmaceuticalsINDUSTRY | 9 | Jun 4, 2026 | clinicaltrials |
| NCT04339400 | A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms | completed | Phase 1 | 79 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03932643 | ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant | completed | Phase 1 | 20 | University of NebraskaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04915612 | Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia | completed | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05534620 | Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics | completed | Phase 1 | 20 | medac GmbHINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT02493530 | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea | completed | Phase 1 | 60 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04742101 | Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 57 | Institut de Recherches Internationales ServierOTHER | 6 | May 18, 2026 | clinicaltrials |
| NCT03600155 | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05155709 | A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 7 | May 7, 2026 | clinicaltrials |
| NCT05441514 | Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04167917 | NTX-301 in MDS/AML | completed | Phase 1 | 22 | University of Alabama at BirminghamOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT03068819 | Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 62 | Washington University School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03009240 | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02204085 | A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 33 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 / Phase 2 | 12 | CRISPR TherapeuticsINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03232268 | HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies(MICROSTEM) | completed | Phase 1 | 25 | Institut Paoli-CalmettesOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03358719 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04620681 | CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML | completed | Phase 1 / Phase 2 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05987696 | Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia | completed | Phase 1 | 2 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04681105 | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | completed | Phase 1 | 13 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04914845 | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | completed | Phase 1 | 16 | University of Colorado, DenverOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05665530 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | completed | Phase 1 | 86 | Prelude TherapeuticsINDUSTRY | 10 | Jan 26, 2026 | clinicaltrials |
| NCT04139434 | Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML | completed | Phase 1 | 32 | Newave Pharmaceutical IncINDUSTRY | 2 | Jan 23, 2026 | clinicaltrials |
| NCT02312102 | Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation | completed | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04220684 | Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML | completed | Phase 1 | 19 | Sumithira VasuOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT03042689 | Study of Regorafenib in Patients With Advanced Myeloid Malignancies | completed | Phase 1 | 16 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05120570 | PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation | completed | Phase 1 / Phase 2 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT01139970 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06882031 | Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia | completed | Phase 1 | 12 | SDK Therapeutics, Inc.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02996773 | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine | completed | Phase 1 | 50 | University of ArizonaOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03263936 | Epigenetic Reprogramming in Relapse/Refractory AML | completed | Phase 1 | 37 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Oct 16, 2025 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials